据港交所2月9日披露，杭州糖吉医疗科技股份有限公司(简称：糖吉医疗)向港交所主板递交上市申请书，工银国际、财通国际为其联席保荐人。招股书披 露，糖吉医疗是一家立足中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供创新解决方案。公司战略构建了涵盖肥胖及代谢性疾病治疗器 械与适配器械及全周期管理产品的产品管线，所有产品均专注于代谢性疾病的治疗及管理，适应证包括超重、肥胖症、伴有肥胖的MASH及伴有肥胖的2型 糖尿病。 ...

智通财经APP获悉，据港交所2月9日披露，杭州糖吉医疗科技股份有限公司(简称：糖吉医疗)向港交所主板递交上市申请书，工银国际、财通国际为其联席 保荐人。招股书披露，糖吉医疗是一家立足中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供创新解决方案。公司战略构建了涵盖肥胖及 代谢性疾病治疗器械与适配器械及全周期管理产品的产品管线，所有产品均专注于代谢性疾病的治疗及管理，适应证包括超重、肥胖症、伴有肥胖的MASH 及伴有肥胖的2型糖尿病。 ...

Core Viewpoint - Aikang Medical (01789) announced that its wholly-owned subsidiary, Beijing Yidian Lingdong Technology Co., Ltd., has successfully won the bid for the orthopedic hip joint surgery navigation system and other equipment projects at the First Affiliated Hospital of Zhejiang University School of Medicine [1] Group 1 - Aikang Medical's subsidiary has secured a significant contract in the medical equipment sector [1] - The project involves advanced technology for orthopedic surgeries, indicating a focus on innovation in healthcare [1]

Core Viewpoint - Aikang Medical (01789) announced that its wholly-owned subsidiary, Beijing Yidian Lingdong Technology Co., Ltd., has successfully won the bid for the orthopedic hip joint surgery navigation system and other equipment projects at the First Affiliated Hospital of Zhejiang University School of Medicine [1] Company Summary - Aikang Medical's subsidiary has secured a significant contract, indicating the company's growth and expansion in the medical technology sector [1]

Group 1 - The company, Aikang Medical, announced that its wholly-owned subsidiary, Beijing Yidian Lingdong Technology Co., Ltd., successfully won the bid for the orthopedic hip joint surgery navigation system project at Zhejiang University School of Medicine First Affiliated Hospital [1] - The K3 intelligent surgical robot system, developed entirely in-house, is designed to be compact and efficient, providing functionalities from preoperative planning to intraoperative assistance, aiming to enhance surgical precision and efficiency [1] - The K3+ robot system received approval from the National Medical Products Administration on January 15, 2026, making it the first all-joint surgical robot in China capable of performing revision surgeries, covering hip, knee, and unicompartmental indications [1] Group 2 - The Visual Treatment Solution (VTS system) integrates medical-engineering interaction for preoperative planning and real-time monitoring, aimed at improving the surgical performance and clinical efficacy of total hip arthroplasty [1] - The company is actively promoting digital orthopedic construction, utilizing smart technology to enhance the diagnostic and treatment levels of medical institutions [2] - The digital orthopedic solutions offered by the company encompass a full range of services, including 3D modeling, surgical planning, 3D model printing, customized surgical tools, and customized prosthetics [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） (股份代號：1789) 自願性公告 業務更新 本公告由愛康醫療控股有限公司（「本公司」，連同其附屬公司稱為「本集團」）自願 作出，以向本公司股東（「股東」）及潛在投資者提供有關本集團最新業務發展的最 新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司全資附屬公司北京壹點靈 動科技有限公司近日成功中標浙江大學醫學院附屬第一醫院骨科髖關節手術導 航系統等設備項目。此外，於2024年12月至2026年1月期間，本集團獲得多項中 標，中標概要載列如下： | | 中標結果╱ | | | --- | --- | --- | | 招標者 | 簽約日期 | 中標公告價格 （人民幣元） | | • 山東省立醫院 | 2024年12月 | （附註） 446萬 | | • 青島市中醫醫院（市海慈醫院） | 2025年08月 | 680 萬 | | • 北京大學第三醫院 | ...

Group 1 - The core viewpoint of the article highlights the recent performance of Kangtong Medical (301515), which closed at 25.92 yuan on February 9, 2026, with a 1.45% increase and a trading volume of 19,600 hands, resulting in a transaction amount of 50.62 million yuan [1] - The company reported a significant decline in its main revenue for the first three quarters of 2025, amounting to 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, down 150.92% [2] - In the third quarter of 2025, the company experienced a quarterly main revenue of 79.12 million yuan, which represents a year-on-year increase of 42.81%, although the net profit attributable to shareholders was still negative at -1.80 million yuan, a decline of 138.94% [2] Group 2 - The company's debt ratio stands at 40.94%, with investment income recorded at -179,400 yuan and financial expenses at 542,400 yuan, while the gross profit margin is reported at 22.45% [2] - The funding flow data indicates that on February 9, 2026, the main funds experienced a net outflow of 1.99 million yuan, accounting for 3.92% of the total transaction amount, while retail investors saw a net inflow of 5.16 million yuan, representing 10.19% of the total transaction amount [1]

Group 1 - The core viewpoint of the news is that Wuzhou Medical (301234) has shown a slight increase in stock price, with a closing price of 41.9 yuan on February 9, 2026, reflecting a 1.4% rise [1] - The company reported a main revenue of 345 million yuan for the first three quarters of 2025, representing a year-on-year increase of 0.82% [2] - The net profit attributable to the parent company for the same period was 18.51 million yuan, showing a significant year-on-year decline of 46.09% [2] Group 2 - In the third quarter of 2025, the company's single-quarter main revenue was 128 million yuan, which is a year-on-year decrease of 1.51% [2] - The net profit attributable to the parent company for the third quarter was 7.99 million yuan, down 36.39% year-on-year [2] - The company's debt ratio stands at 12.32%, with an investment income of 3.67 million yuan and a financial expense of -2.07 million yuan [2] Group 3 - The company operates in the field of research, production, and sales of disposable sterile infusion medical devices, primarily using an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand owners [2] - The gross profit margin for the company is reported at 14.22% [2] Group 4 - On February 9, 2026, the net inflow of main funds was 762,700 yuan, accounting for 2.21% of the total transaction amount [1] - Retail investors saw a net inflow of 1.40 million yuan, representing 4.06% of the total transaction amount, while speculative funds experienced a net outflow of 2.17 million yuan, which is 6.27% of the total transaction amount [1]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

惠泰医疗(688617.SH)发布公告，公司拟1.5亿元至2亿元回购股份，回购股份价格不超过315元/股，回购 的股份将在未来适宜时机用于员工持股计划或股权激励。 ...